Acrivon Therapeutics, Inc. · NASDAQ:ACRV

Blume-Jensen Peter sold 1,780 Acrivon Therapeutics, Inc. shares (Form 4)

Traded Nov 17, 2026 · Filed Nov 19, 2026

On Nov 17, 2026, Blume-Jensen Peter (Director, President and CEO) sold 1,780 Acrivon Therapeutics, Inc. shares at US$1.45 for US$2,581, leaving 385,355 shares. Filed Nov 19, 2026 (Form 4).

Sold
1,780 shares
Price
US$1.45
Value
US$2,581
Holding after
385,355 shares (held indirectly)
Trading plan
No
Role
Director, President and CEO

The filing in full

DateSecurityTransactionSharesPriceHolding afterOwnership
Nov 17, 2026Common StockSale1,276US$1.452,228,776Direct
Nov 17, 2026Common StockSale504US$1.45385,355Indirect

Source

Download original · View original at SEC

Related